I-07 Yumi Yamamoto
Development of a generic model for brain distributional pharmacokinetics and its translation to clinical data
Wednesday 10:20-11:40 |
I-08 Gregory Ferl
Mechanistic model of amyloid beta (Aß) and anti-Aß mAb dynamics
Wednesday 10:20-11:40 |
I-13 Nicolas Frey
Model-based meta-analysis of amyloid plaque reduction in Alzheimer’s disease patients to identify new Phase 3 doses and dosing regimens for Gantenerumab
Wednesday 10:20-11:40 |
I-58 Marija Jovanovic
Population pharmacokinetic model of topiramate and its major metabolite in adult epileptic patients
Wednesday 10:20-11:40 |
I-60 Tatiana Karelina
Clinical trial simulation and hypothesis testing using amyloid pathology longitudinal translational model
Wednesday 10:20-11:40 |
I-69 Max Lagraauw
A population disease progression model for Amyotrophic Lateral Sclerosis – Results of the Treeway Summer Challenge 2015
Wednesday 10:20-11:40 |
I-73 Mary Lavy
Population Pharmacokinetics (PK) and Pharmacodynamics (PD) of Natalizumab in Patients with Multiple Sclerosis (MS)
Wednesday 10:20-11:40 |
II-03 Malidi Ahamadi
Population exposure –response analysis of “On-Off” time in Individuals with Parkinson Disease following Preladenant Treatment
Wednesday 15:10-16:30 |
II-08 Silvana Alvariza
Autoinduction of phenytoin hepatobiliary secretion as a mechanism for its nonlinear pharmacokinetics
Wednesday 15:10-16:30 |
II-26 Irina Bondareva
External validation and predictability of nonlinear models for changes in steady–state pharmacokinetics (PK) of carbamazepine (CBZ) and valproate (VPA) due to antiepileptic drug-drug interactions using sparse therapeutic drug monitoring (TDM) data
Wednesday 15:10-16:30 |
II-53 Valerie Cosson
Amyloid related imaging abnormalities (ARIA): Time to event modeling to identify new Phase 3 doses and dosing regimens for Gantenerumab
Wednesday 15:10-16:30 |
II-58 Fabrizia D'Antonio
Effect of psychotic subtypes on cognitive trajectories in Alzheimer’s disease Neuroimaging Initiative ADNI2.
Wednesday 15:10-16:30 |
III-03 Andreas Lindauer
Time-to-seizure modeling of the antiepileptic drug lacosamide used in monotherapy
Thursday 10:05-11:30 |
III-16 Amelie Marsot
Population pharmacokinetic model of delta-9-tetrahydrocannabinol (THC) in cannabis occasional smokers
Thursday 10:05-11:30 |
III-43 Theodoros Papathanasiou
Population modelling of the synergistic effects of morphine and gabapentin in the rat: a response surface approach
Thursday 10:05-11:30 |
III-66 Su-jin Rhee
A population pharmacokinetic analysis of levetiracetam in patients with epilepsy
Thursday 10:05-11:30 |
IV-20 Eva Sverrisdottir
Pharmacokinetic Metamodel of Morphine and Morphine-6-Glucuronide in Neonates and Adults
Thursday 14:40-16:00 |
IV-23 Paulo Teixeira
The Effect of Anthropometric Covariates on Clearance of Valproic Acid.
Thursday 14:40-16:00 |
IV-36 Iñaki F. Trocóniz
Markov Model for Lithium Compliance Assessment
Thursday 14:40-16:00 |
IV-37 Max Tsai
Modelling of Pharmacokinetics and the Incidence of Adverse Events of the PDE-10A Inhibitor TAK-063
Thursday 14:40-16:00 |
IV-44 Sven van Dijkman
Differentiation between Parkinson’s and Parkinson’s-like patients in MDS-UPDRS-based diagnosis
Thursday 14:40-16:00 |
IV-69 Seonghae Yoon
Population pharmacokinetic analysis of oxcarbazepine in patients with epilepsy
Thursday 14:40-16:00 |
